Last reviewed · How we verify
NCT07200362
Study of Compound Nanxing Zhitong Ointment in the Treatment of Chronic Pain in Musculoskeletal System
trial testing Compound Nanying zhitong Ointment in Chronic Primary Musculoskeletal Pain in 3,029 participants. Completed in 28 February 2024.
14 June 2023
Quick facts
| Lead sponsor | Jiangsu Kanion Pharmaceutical Co., Ltd |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,029 |
| Start date | 30 October 2021 |
| Primary completion | 14 June 2023 |
| Estimated completion | 28 February 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Compound Nanying zhitong Ointment — full drug profile →
- Do not use any other similar proprietary medicines or traditional Chinese medicines.
Conditions studied
- Chronic Primary Musculoskeletal Pain — all drugs for Chronic Primary Musculoskeletal Pain →
Sponsor
Jiangsu Kanion Pharmaceutical Co., Ltd — full company profile →
Who can join
Eligibility, any sex, with Chronic Primary Musculoskeletal Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective cohort study on the treatment of chronic pain in the musculoskeletal system with Compound Nanxing Pain Relief Ointment. This study adopted an observational research design. Through a cohort study, patient medical records were collected to meet the criteria of chronic pain classification in International Classification of Diseases 11th Revision (ICD-11), which is located in the musculoskeletal system and occurs in the neck and shoulders, waist and back, limbs, and meets the diagnostic criteria of "cold syndrome" in traditional Chinese medicine. The target population was selected to evaluate the clinical effects of Compound Nanxing Pain Relief Ointment in treating chronic pain in the musculoskeletal system, reducing pain, improving muscle and bone function status, and enhancing quality of life. The study aimed to compare the heterogeneity of the clinical effects of Compound Nanxing Pain Relief Ointment in treating chronic pain in the musculoskeletal system. The study plan included 3000 patients, and no intervention in treatment and medication was provided to the patients during the observation period. The shortest medication duration was 2 weeks, and the longest observation period was 3 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07200362
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Jiangsu Kanion Pharmaceutical Co., Ltd trials
Trials by the same sponsor.
- NCT07126171 — A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever · NA · not yet recruiting
- NCT06679998 — A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection · Phase 1 · not yet recruiting
- NCT05192304 — Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07200362 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Kanion Pharmaceutical Co., Ltd
- Last refreshed: 1 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07200362.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing